Leadiant Hit By Second Complaint Over Price Of CTX Drug In Europe

 
• By Ian Schofield
  
Generate a summary of this article
Listen to this article
Beta

A second complaint has been filed, this time in Belgium, over the “excessive” price hike on Leadiant’s CDCA-containing drug for the rare genetic disorder, CTX.

MoneyPill
The price of Leadiant's CTX drug is again under scrutiny • Source: Shutterstock

The Belgian consumer organization, Test Aankoop, has decided to file a complaint with the country’s competition authority regarding what it calls the “excessive” price of Leadiant Biosciences Inc.’s chenodeoxycholic acid (CDCA) product, which is used to treat the rare genetic condition cerebrotendinous xanthomatosis (CTX). A similar complaint was filed in the Netherlands last year.

Test Aankoop says that Leadiant markets “an old molecule as an orphan drug,” has increased the product’s price by a...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By Saba Afreen

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     
    • By Anabel Costa-Ferreira and Ian Schofield

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography